TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01697657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily before meals for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily before meals for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
Study: NCT00758524

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LCI699-matching Placebo
Description: LCI699-matching placebo oral capsules
Study: NCT04502745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Cortical Access System (MICAS)
Description: Temporary surgical tool that provides access to the sub-dural space through the cranium.
Study: NCT04038723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: Cardiac patients have completed 36 times of exercise training with the exercise frequency of 2-3 times per week. Subjects performed five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak after the warm-up period. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak.
Study: NCT04428619

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Electrical Nerve Field Stimulation (PENFS) Device
Description: Patients will complete daily worst abdominal pain and bowel habit questionnaires for 1 week prior to initial PENFS device placement to provide a baseline. At visit 1, patients will complete the Bowel Symptom Questionnaire, IBS Symptom Severity Scale (IBS-SSS), PROMIS Belly Pain Scale, Gas and Bloating, Constipation, and Diarrhea Scales, Hospital Anxiety and Depression Scale, and Visceral Sensitivity Index, heart rate variability will be measured, and they will have the initial PENFS device placed. Patients will complete daily worst abdominal pain (scale 0-10) questionnaires throughout the duration of the study. They will return every 7 days for a total of 4 visits for device replacement and additional questionnaires, including the IBS-SSS. Four devices will be placed in total (start of weeks 1, 2, 3, and 4). Stimulation time is 5 days/week during each of the 4 consecutive weeks. Additional questionnaires will be completed at the end of week 4 and at extended follow-up (8 weeks).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Patients will complete daily worst abdominal pain and bowel habit questionnaires for 1 week prior to initial sham device placement to provide a baseline. At visit 1, patients will complete the Bowel Symptom Questionnaire, IBS Symptom Severity Scale (IBS-SSS), PROMIS Belly Pain Scale, Gas and Bloating, Constipation, and Diarrhea Scales, Hospital Anxiety and Depression Scale, and Visceral Sensitivity Index, heart rate variability will be measured, and they will have the initial sham device placed. Patients will complete daily worst abdominal pain (scale 0-10) questionnaires throughout the duration of the study. They will return every 7 days for a total of 4 visits for device replacement and additional questionnaires, including the IBS-SSS. Four devices will be placed in total (start of weeks 1, 2, 3, and 4). Stimulation time is 5 days/week during each of the 4 consecutive weeks. Additional questionnaires will be completed at the end of week 4 and at extended follow-up (8 weeks).
Study: NCT03966599

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pain
Description: Patient's pain in order to VAS

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pain
Description: Patient's pain in order to VAS

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hemodynamic changes
Description: changes in hemodynamic states

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hemodynamic changes
Description: changes in hemodynamic states
Study: NCT01693393

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclosporine A
Description: Patients will receive Cyclosporine A in a dose of ca. 2mg/kg/BW daily for a 16 week period
Study: NCT01295619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-020805
Description: A thin layer of I-020805 applied up to two times on the sutured dura mater
Study: NCT02275806

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Study: NCT03331276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BBN
Description: BBN to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brand
Description: Brand to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
Study: NCT03185858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SINEMA intervention
Description: Provider-facing intervention includes the following components:~(1) Systematic cascade training for village doctors; (2) monthly follow-up visits with the support of the SINEMA APP; (3) village doctor group activities; (4) performance feedback and incentives.~Stroke survivor-facing intervention program includes the following components:~(1) Briefing session; (2) monthly follow-up visits and follow-up handout; (3) daily voice message for health education.
Study: NCT00110279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)
Description: Live attenuated H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)
Description: Live attenuated H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
Study: NCT00758524

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LCI699-matching Placebo
Description: LCI699-matching placebo oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eplerenone-matching Placebo
Description: Eplerenone-matching placebo oral capsules
Study: NCT03991325

Intervention type: DIAGNOSTIC_TEST
Intervention: upper airway sonography
Description: clinical evaluation of upper airway, ultrasonographic assessement

Intervention type: DIAGNOSTIC_TEST
Intervention: upper airway sonography
Description: clinical evaluation of upper airway, ultrasonographic assessement
Study: NCT00996905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable ultrasound machine
Description: Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable ultrasound machine
Description: Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
Study: NCT00758524

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eplerenone-matching Placebo
Description: Eplerenone-matching placebo oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eplerenone-matching Placebo
Description: Eplerenone-matching placebo oral capsules
Study: NCT01476137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: MEK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: MEK inhibitor
Study: NCT03678246

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ramped position
Description: LSFOI glottis view
Study: NCT01476137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: MEK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: MEK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: MEK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: MEK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: MEK inhibitor
Study: NCT03678246

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ramped position
Description: LSFOI glottis view

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supine position
Description: LSFOI glottis view
Study: NCT01476137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: MEK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183
Description: AKT inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183
Description: AKT inhibitor
Study: NCT03678246

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supine position
Description: LSFOI glottis view
Study: NCT01476137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183
Description: AKT inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183
Description: AKT inhibitor
Study: NCT03029104

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: CXLO Corneal Strengthening Solution and UVA Illumination Device
Description: CXLO Corneal Strengthening Solution
Study: NCT03839420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CZM IOL
Description: implantation of CZM IOL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Competitor IOL
Description: implantation of Competitor IOL
Study: NCT04700670

Intervention type: BIOLOGICAL
Intervention: measurement of anti-Xa activities
Description: The measurement of anti-Xa activities will be carried out on frozen-defrosted plasma citrate and CTAD with 4 reagents~* STA-Liquid anti-Xa (STAGO) (not containing dextran)~* Biophen Heparin LRT (Hyphen) (reactive containing dextran)~* Berichrom (Siemens) with dextran~* Berichrom (Siemens) without dextran~The dosage of platelet factor 4 and of the beta-TG will be carried out on frozen-defrosted plasma with the asserachrom PF4 and Asserachrom beta-TG (Diagnostica Stago) kits.

Intervention type: BIOLOGICAL
Intervention: measurement of anti-Xa activities
Description: The measurement of anti-Xa activities will be carried out on frozen-defrosted plasma citrate and CTAD with 4 reagents~* STA-Liquid anti-Xa (STAGO) (not containing dextran)~* Biophen Heparin LRT (Hyphen) (reactive containing dextran)~* Berichrom (Siemens) with dextran~* Berichrom (Siemens) without dextran~The dosage of platelet factor 4 and of the beta-TG will be carried out on frozen-defrosted plasma with the asserachrom PF4 and Asserachrom beta-TG (Diagnostica Stago) kits.
Study: NCT04433897

Intervention type: OTHER
Intervention: Questionnaire
Description: All women fulfilled 3 questionairres~* TANGO~* ICIQ -N~* Perceived Stress Scale

Intervention type: OTHER
Intervention: Questionnaire
Description: All women fulfilled 3 questionairres~* TANGO~* ICIQ -N~* Perceived Stress Scale

Intervention type: OTHER
Intervention: Questionnaire
Description: All women fulfilled 3 questionairres~* TANGO~* ICIQ -N~* Perceived Stress Scale
Study: NCT01850901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation
Study: NCT04433897

Intervention type: OTHER
Intervention: Questionnaire
Description: All women fulfilled 3 questionairres~* TANGO~* ICIQ -N~* Perceived Stress Scale

Intervention type: OTHER
Intervention: Questionnaire
Description: All women fulfilled 3 questionairres~* TANGO~* ICIQ -N~* Perceived Stress Scale

Intervention type: OTHER
Intervention: Questionnaire
Description: All women fulfilled 3 questionairres~* TANGO~* ICIQ -N~* Perceived Stress Scale

Intervention type: OTHER
Intervention: Questionnaire
Description: All women fulfilled 3 questionairres~* TANGO~* ICIQ -N~* Perceived Stress Scale

Intervention type: OTHER
Intervention: Questionnaire
Description: All women fulfilled 3 questionairres~* TANGO~* ICIQ -N~* Perceived Stress Scale

Intervention type: OTHER
Intervention: Questionnaire
Description: All women fulfilled 3 questionairres~* TANGO~* ICIQ -N~* Perceived Stress Scale

Intervention type: OTHER
Intervention: Questionnaire
Description: All women fulfilled 3 questionairres~* TANGO~* ICIQ -N~* Perceived Stress Scale
Study: NCT03741543

Intervention type: OTHER
Group type: OTHER
Intervention: A 12-week health promotion course
Description: The Health Promotion intervention consists of 12 weekly 2-hour sessions with a group of up to six participants and two course facilitators. Teaching methods includes lecture, questions- and answer periods, and interactive hands-on learning. During the class sessions, the facilitators encourages the participants to ask questions and make comments about the lecture at any time. During the first class session, each participant receives a booklet with the course material.
Study: NCT05666648

Intervention type: OTHER
Intervention: Sitz Bath
Description: Individual patients were randomized to either receive 'sitz baths' or 'no sitz baths' treatment for 4 weeks. Patients were asked to have 'sitz bath' once in morning and again at bedtime, after each week pain scores and healing of fissure were assessed. Main outcome measures were validated
Study: NCT03359655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Rectal administration 2 jours before the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine butyl bromide
Description: Rectal administration 2 jours before the procedure
Study: NCT02222922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06647020 Q3W
Description: Part 1: PF-06647020 will be administered intravenously every 21 days in cohorts of 2-4 patients starting at a dose of 0.20mg/kg. Increases in dose will continue until MTD is determined.~Part 2: Patients with triple negative breast cancer (pre-selected for PTK7 moderately high to high expression), non small cell lung cancer (pre-selected with moderate to high PTK7 expression) and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluconazole
Description: combination drug used for drug-drug interaction sub-study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06647020 Q2W
Description: Part 1: PF-06647020 will be administered intravenously every 14 days in cohorts of 2-4 patients starting at a dose of 2.1 mg/kg. Increases in dose will continue until MTD is determined.~Part 2: Patients with non-small cell lung cancer (pre-selected for PTK7 moderate to high expression and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06647020 combined with Avelumab
Description: Part 2: Patients with ovarian cancer (unselected for PTK7 expression) will be treated with PF-0664702 plus Avelumab.
Study: NCT00098839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Description: Given IM
Study: NCT00478062

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hodgkin's antigens-GM-CSF-expressing cell vaccine
Study: NCT00098839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study: NCT00478062

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study: NCT00098839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: 40 mg/m2/day PO divided BID or TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: 40 mg/m2/day PO divided BID or TID
Study: NCT02070965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD01 Spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD01 Spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comp01 Lotion
Study: NCT03277443

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer guided surgery
Description: Preoperative surgical simulation and immediate postoperative evaluation will be carried out using Multi Slice CT scan.Craniofacial images from 3D computerized tomography (3D-CT scan) can be used to create a 3D model, which can in turn be used for 3D Cephalometry measurements and surgical simulation.The process of 3D-model contains mounting of 3D virtual models in a 3D virtual articulator; and repositioning of 3D virtual models according to the STO then Fabrication of a 3D virtual intermediate surgical wafer; and materialization of the surgical wafer using a stereolithographic technique. The 3D model can produce actual movement of surgical cuts and movement of segments accordingly

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional model surgery
Description: preparation for orthognathic surgery which involves diagnosis with 2D cephalometric radiograph, face-bow transfer and model surgery on plaster dental cast, and fabrication of intermediate and final occlusal splint.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2D cephalometric radiograph
Description: 2D cephalometric radiograph

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D computerized tomography
Description: 3D computerized tomography
Study: NCT04234308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyglycolic Acid
Description: Periodontal and periimplant flaps closed with at least one suture with Polyglycolic Acid Absorbable suture, synthetic, 4-0. (TAGUM®).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catgut
Description: Periodontal and periimplant flaps closed with at least one suture with Chromic Gut Absorbable suture, natural, 4-0. (TAGUM®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene
Description: Periodontal and periimplant flaps closed with at least one suture with expanded Polytetrafluoroethylene Non absorbable suture, synthetic, 4-0. (TAGUM®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyamide
Description: Periodontal and periimplant flaps closed with at least one suture with Nylon Non absorbable sutures, synthetic, 4-0. (TAGUM®)
Study: NCT02839772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Current skin care regimen plus 2% glycerine added to soaking water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current skin care regimen
Study: NCT04949217

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inlay Bristow
Description: A modified Bristow procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bristow
Description: Traditional Bristow procedure
Study: NCT03290378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: IV; 25 mg or 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: IV; 25 mg or 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV; Placebo, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
Study: NCT04099745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM
Description: Continuous Glucose Monitoring System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FGM
Description: Flash glucose monitoring System
Study: NCT03055624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embosphere microparticles for prostate artery embolization
Description: Pelvic angiograms will be performed and microspheres delivered to the arteries supplying the prostate to alleviate symptoms of benign prostatic hyperplasia.
Study: NCT01274702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Reconstitutions Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saccadic Eye Movement Training
Study: NCT00810212

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PLF with autograft
Description: 6 subjects

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLF with NeoFuse
Description: 6 subjects low dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLF with NeoFuse
Description: 6 subjects medium dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLF with NeoFuse
Description: 6 subjects high dose
Study: NCT04633317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A pneumatic nebulizer
Description: Inhaled colistimethate sodium generated by a pneumatic nebulizer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A vibrating mesh nebulizer
Description: Inhaled colistimethate sodium generated by a vibrating mesh nebulizer
Study: NCT03024502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPP-AF Gel 1%
Description: Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPP-AF Gel 2%
Description: Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotrimazole
Description: Administration intravaginal of clotrimazol, 1x/day, 7 days
Study: NCT00970346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OligoG CF-5/20
Description: Inhaled OligoG CF-5/20 will be given to healthy volunteers with different concentrations to test tolerability of the drug